08:44 AM EDT, 08/12/2025 (MT Newswires) -- ProPhase Labs ( PRPH ) said Tuesday that the US Patent Office has issued a patent covering its biomarker-based systems and methods to assess progression risk in Barrett's esophagus and esophageal adenocarcinoma, a type of cancer.

Shares of the company rose more than 38% pre-bell Tuesday.

The patent issuance follows the company's BE-Smart molecular diagnostic achieving a greater than a 95% technical success rate in detecting its patented panel of biomarkers, the company said.

Price: 0.39, Change: +0.11, Percent Change: +38.30